Mid-Term Clinical Outcomes and Hemodynamic Performance of 19-mm Bioprostheses Following Aortic Valve Replacement　― A Single-Institution 10-Year Experience ―

Key Result

Surgical AVR with 19-mm third-generation bioprostheses in small aortic annulus patients showed overall survival rates of 93.0% at 1 year, 87.0% at 3 years, and 85.7% at 5 years, with stable hemodynamics and 28% moderate-to-severe prosthesis-patient mismatch.

Key Points

• Clinical outcomes indicate that 19-mm bioprostheses provided satisfactory performance over a 10-year period.
• Hemodynamic performance metrics suggest that smaller valves can maintain effective cardiac function after replacement.
• Evaluation included detailed assessment of patients undergoing aortic valve replacement with 19-mm bioprostheses.
• Findings highlight the need for more data on smaller bioprostheses to inform future surgical decisions.